The Phamarceutical Benefits Advisory Committee has recommended the listing of tenofovir alafenamide (TAF) for the treatment of chronic hepatitis B.

Marketed as Vemlidy, TAF is currently listed for the treatment of HIV. It can achieve the same level of virus suppression with one-tenth the dosage of the current tenofovir drug Viread and hence has less side-effects.